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Abstract: The activity of the mitochondrial permeability transition pore, mPTP, a highly regulated
multi-component mega-channel, is enhanced in aging and in aging-driven degenerative diseases.
mPTP activity accelerates aging by releasing large amounts of cell-damaging reactive oxygen species,
Ca2+ and NAD+. The various pathways that control the channel activity, directly or indirectly, can
therefore either inhibit or accelerate aging or retard or enhance the progression of aging-driven
degenerative diseases and determine lifespan and healthspan. Autophagy, a catabolic process
that removes and digests damaged proteins and organelles, protects the cell against aging and
disease. However, the protective effect of autophagy depends on mTORC2/SKG1 inhibition of mPTP.
Autophagy is inhibited in aging cells. Mitophagy, a specialized form of autophagy, which retards
aging by removing mitochondrial fragments with activated mPTP, is also inhibited in aging cells, and
this inhibition leads to increased mPTP activation, which is a major contributor to neurodegenerative
diseases, such as Alzheimer’s and Parkinson’s diseases. The increased activity of mPTP in aging
turns autophagy/mitophagy into a destructive process leading to cell aging and death. Several drugs
and lifestyle modifications that enhance healthspan and lifespan enhance autophagy and inhibit the
activation of mPTP. Therefore, elucidating the intricate connections between pathways that activate
and inhibit mPTP, in the context of aging and degenerative diseases, could enhance the discovery of
new drugs and lifestyle modifications that slow aging and degenerative disease.
Keywords: mitochondrial permeability transition; aging; longevity; aging-driven degenerative
disease; reactive oxygen species; mitophagy; autophagy; Parkinson’s disease
1. Introduction: The Mitochondrial Permeability Transition Pore
The mitochondrial permeability transition pore (mPTP) is a mitochondrial inner
membrane multicomponent mega-channel, with variable conductance (up to 1.5 nS) that
is activated by calcium, oxidative stress and membrane depolarization [1,2]. The channel
exhibits several conductance states with variable duration. When activated, protons flow
into the matrix, while calcium, superoxide, hydrogen peroxide and other ions flow out of
the matrix and the mitochondrial protonmotive force (∆Ψ + ∆pH) collapses, thus inhibiting
oxidative phosphorylation. The high conductance pore, when fully open, also allows
the passage of large solutes, with MW up to 1.5 KDa, and the outflow of respiratory
substrates from the matrix, which are normally held at a high concentration in the matrix
by the protonmotive force, inhibits electron transport, while flooding the matrix with
cytosolic solutes leads to swelling of the mitochondrial matrix and eventually rupture of
the outer mitochondrial membrane. The inhibition of oxidative phosphorylation depletes
cellular ATP and therefore extensive and prolonged activation of mPTP may lead to cell
death by necrosis; in addition, the rupture of the mitochondrial outer membrane releases
proapoptotic proteins, including cytochrome c, AIF and endonuclease, thereby inducing
cell death by apoptosis or similar processes [3–10]. Oxidative stress-dependent cell death
largely depends on the activation of mPTP. Lower conductance states with a short duration
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of partial activation may release only small solutes and ions, such as superoxide, hydrogen
peroxide and calcium, and this release may play an important role in H2O2 and Ca2+
signaling [11–13]. For example, mPTP-mediated superoxide flashes regulate cortical neural
progenitor differentiation [12]. Moderate activation of mPTP may be insufficient to cause
cell death but may result in damage to both mitochondrial and cellular proteins, lipids and
DNA and thus accelerate cell aging [14].
The exact composition of mPTP is still not fully resolved. There are several mitochon-
drial proteins that were shown to participate in the channel activity, such as cyclophilin
D (CypD), adenine nucleotide translocase (ANT), ATP synthase, the outer membrane
voltage-dependent anion channel (VDAC), the phosphate carrier (PiC) and SPG-7. Be-
cause CyPD is not a transmembrane protein it cannot form a channel on its own, but it
binds to pore-forming protein(s) and regulates their channel activity, as is evident from
the inhibitory effect of its ligand cyclosporin A [15–17]. Reconstitution of ANT, VDAC,
PiC, ATP synthase and subunit c of ATP synthase in liposomes, or in planar phospholipid
membranes, showed that a channel can be formed that exhibits, at least in part, the proper-
ties of mPTP. However, genetic ablation studies of each one of these candidate proteins
showed that none of these proteins is essential for mPTP activity, although the residual
activity was always somewhat different from mPTP activity in wt mitochondria [1,18]. The
fact that mPTP can be induced in cells depleted of mtDNA suggests that the composition
and activity of the pore does not require mtDNA-coded proteins [19]. The inescapable
conclusion from these studies is that some combination of these proteins is necessary to
fully exhibit the properties of mPTP [1,18,20,21]. Because experiments with ATP synthase
and ANT provided the strongest evidence for participation in the mPTP channel, it was
recently suggested that both ATP synthase and ANT are required for the formation of a
fully functional mPTP channel, although the nature of this composite channel remains
elusive [1,20,21]. Moreover, the contribution of several other proteins to mPTP activity is
still unresolved. In particular, the outer membrane transporter VDAC has been shown, by
several studies, to control mPTP activity [6,22–27]. It was previously shown that VDAC
interacts with ANT to form a channel [28] and that the reconstitution of a complex of
ANT/VDAC/CypD exhibits mPTP-like activities [29]. Moreover, VDAC was shown to
lock ANT in the C conformation [30], which is known to activate mPTP [2,31]. A recent
study demonstrated the co-immunoprecipitation of SGK1/VDAC1 with nearly all other
protein candidates for the mPTP channel, i.e., ANT1, ANT3, two peptides of ATP syn-
thase (OSCP and subunit delta), SPG-7 and PiC, but no other mitochondrial proteins [27].
Furthermore, the effects of VDAC1 accumulation on mPTP activation, autophagy and
lifespan were dependent on ANT1 [27], suggesting that the activation of mPTP by VDAC1
is mediated by the VDAC/ANT complex.
2. Aging and Enhanced mPTP Activity
Aging is a process of gradual accumulation of damage to cellular proteins, lipids, DNA
and cell organelles, leading to cellular, organellar and organ dysfunctions, resulting in
aging-driven diseases, cell death and finally organism death [32–34]. It is now recognized
that mitochondrial dysfunction is a major contributor to aging and aging-driven degenera-
tive disease, such as diabetes, heart diseases, cancer, Alzheimer’s disease and Parkinson’s
disease [35–40]. Mitochondrial dysfunction in aging is often manifested as the excess
production of mROS, calcium overloading, and membrane depolarization. Since these
dysfunctions are known to activate mPTP [2], it can be expected that mPTP activity will be
enhanced in dysfunctional mitochondria in aging. Indeed, direct evidence for enhanced
mPTP activation in aging and neurodegenerative disease is extensive. This evidence has
been reviewed frequently and will not be described in detail in this review [41–46].
It has been recognized for a long time that mitochondria are the major source of ROS
in the cell and that oxidative damage to phospholipids, proteins, mtDNA and nuclear DNA
in aging results from the excess production of mROS [47–52]. Mitochondrial metabolic
reactions continuously generate superoxide from several sources, including the citric acid
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cycle enzymes and electron transport enzymes with variable rates that depend on the
metabolic pathways, on the redox state of key components and on the mitochondrial
membrane potential [53–58]. However, the mitochondrial matrix also contains a robust
system that converts superoxide to H2O2 (SOD2), and several peroxidases that regulate the
level of H2O2 in the matrix [59]. While the mitochondrial inner membrane is impermeable
to both superoxide and H2O2 [60], a water channel, aquaporin 8 (AQP8), allows the
diffusion of H2O2 to the outer compartment [61] and, eventually, through VDAC to the
cytoplasm. That flow of H2O2 from the mitochondria to the cytoplasm largely controls the
redox balance in the cytoplasm. A metabolically induced change in H2O2 flow from the
mitochondria will change the redox balance in the cell, which exerts its effects on metabolic
pathways, through its impact on -SH residues on critical proteins [62]. In recent years, it
has become apparent that a moderate increase in mROS production is actually beneficial
to the cell as it serves as a signal to the nucleus to activate a number of mechanisms
that protect the cell, and particularly the mitochondria, from the destructive effects of
mROS [63–68]. Partial, short duration openings of mPTP can generate a pulse of H2O2, Ca2+
and superoxide that may serve as signals for several physiological processes [11–13,69,70].
What determines whether the channel opens for a short or long duration is not entirely
clear [71]. However, a full and longer lasting opening of the pore can generate a large
excess of superoxide and H2O2 release that can overpower the mitochondrial and cellular
antioxidant systems and cause damage to membrane phospholipids, enzymes, transporters
and most importantly DNA [72]. The mROS released by the activation of mPTP at one
mitochondrial site may activate mPTP at an adjacent site and this second opening can
then trigger opening at other sites, creating a propagating wave of mPTP opening across
the cell [54]. The opening of mPTP, in addition to the fast release of the mROS content of
the matrix, induces further production of superoxide while the mPTP remains open. It
appears that the inhibition of oxidative phosphorylation rather than inhibiting superoxide
production actually stimulates the production of mROS at specific sites [73–76]. When
mPTP is fully activated, and this activation is propagated throughout the cell, the inevitable
outcome is cell death, as described above, unless the process can be stopped or reversed
before the cell death processes progress. The opening of mPTP can be reversed readily
if the pore is only partially open since Ca2+, which is required to keep the pore open,
is lost quickly; in addition, proton flow into the matrix lowers the pH, which inhibits
the channel [2], and membrane potential is restored to close the pore. However, when
the pore is fully open, the mitochondrial respiratory substrates that are at much higher
concentrations in intact mitochondria would be lost during the opening of mPTP, and
electron transport cannot recover unless the substrates are taken up by the mitochondria,
a process that itself depends on the proton motive force. Nevertheless, ATP, which is
normally at a higher concentration in the cytoplasm than in the matrix, could flow through
the pore into the mitochondria and reverse the ATPase, which would restore the proton
motive force [77–79]. This would close the pore and drive the re-accumulation of respiratory
substrates, restarting oxidative phosphorylation, and allow the mitochondria to recover.
Thus, unless the mPTP activation has propagated massively, and cellular ATP is already
depleted, the mitochondrion can recover after full activation of mPTP. However, the
oxidative damage to mitochondrial and cellular proteins, lipids and DNA, that was done
by the extended production of mROS, cannot be fully erased, and cell aging will progress.
Another critical mechanism that can stop the propagation of mPTP opening in the cell is
the removal of mitochondria with activated mPTP by mitophagy, a process that protects
the cell from progression to apoptosis, reduces oxidative damage and retards aging (see
below). An additional deleterious outcome of extended mPTP opening is the loss of NAD+.
NAD+ is the substrate of both the NAD+-dependent deacetylases, sirtuins and PARP1,
that coordinate DNA repair. The loss of NAD+ from the mitochondrial matrix inhibits the
mitochondrial sirtuins (sirt3, sirt4, sirt5), resulting in increased mROS generation [80], and
also enhanced activity of mPTP because CypD is inhibited by deacetylation by sirt3 [81,82].
Therefore, even when the mPTP opening is reversed, and the mitochondria recover, the
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loss of NAD+ would leave the mitochondria more susceptible to a second opening of
the pore [83]. Moreover, the NAD+ that exits the matrix into the outer compartment is
hydrolyzed by CD38, depleting the cellular pool of NAD+ [3,84], thus also inhibiting
cytoplasmic sirtuins (e.g., sirt1). In addition, the release of mROS by mPTP opening
activates PARP1 which further depletes cellular NAD+ [85,86]. It is now recognized that
one of the major causes of aging and degenerative disease is the depletion of NAD+ in aging
cells [87–92]. CD38 expression increases with age, which further enhances the destructive
effects of mPTP opening in aging [93]. The fact that the opening of mPTP further enhances
the production of damaging mROS and leads to the cellular depletion of NAD+ led us to
suggest that mPTP activity is critical for the progression of aging [14].
The oxidative damage to cell proteins, lipids and most importantly nuclear DNA is
now believed to be a critical element of the aging process [94–100]. Oxidative damage to
nuclear DNA elicits the DNA damage response that induces both proapoptotic pathways
and protection pathways [101]. Several protection pathways depend on induction by
mROS of PARP1, which repairs damaged DNA in an NAD+-dependent manner [102],
and on the induction of NAD+-dependent deacetylases, the sirtuins [103,104]. Of critical
importance is sirt1, which deacetylates a number of critical proteins [88,105,106]. Similar to
deacetylases, histone demethylases also contribute to stress-induced protection [107]. In
addition to inducing protection of nuclear DNA from oxidative damage, mROS initiate sig-
nals that activate several pathways that protect mitochondria from oxidative stress. These
pathways slow aging, inhibit cell death and may result in lifespan extension [67,108,109].
The mitochondrial sirtuins (sirt3–5), and particularly sirt3, are critical in the protection of
mitochondria [80,110,111]. Other pathways that protect the mitochondria are the mitochon-
drial unfolded protein response, UPR(mt), which enhances mitochondrial homeostasis
by enhancing the expression of mitochondrial chaperones [112–116], and the nrf2 antiox-
idant response, which protects against mROS-induced mitochondrial damage and cell
death [117–120]. The induction of PGC1alpha, which initiates mitochondrial biosynthesis,
is also important in displacing dysfunctional mitochondria [121], and is the main mecha-
nism by which physical exercise delays aging and protects from aging-related degenerative
diseases (see below). Another important pathway that is now recognized as playing a
major role in delaying aging and degenerative disease is autophagy and its mitochondrion-
specific form, mitophagy (discussed below). All the protection pathways inhibit mPTP
activity either directly, by regulating the expression or by posttranslational modification of
mPTP components, or indirectly, by inhibiting mROS production or calcium overloading,
or by eliminating damaged mitochondria by mitophagy, or by inducing the biosynthesis of
new mitochondria. In contrast, several proapoptotic pathways (e.g., P53, p66Shc) enhance
mPTP activity [122–125]. Figure 1 shows the major pathways that enhance or inhibit the
activation of mPTP in aging.




Figure 1. The control of mitochondrial permeability transition pore (mPTP) activity determines the progression of aging. 
Full opening of mPTP, which is activated by excess mitochondrial calcium loading and/or excess mROS production, re-
leases large amounts of calcium, NAD+ and mROS from the mitochondrial matrix. The released NAD+ is hydrolyzed by 
CD38, and the loss of NAD+ enhances the progression of aging by inhibiting sirtuins and PARP1. The release of large 
amounts of mROS causes nuclear DNA damage which enhances apoptotic signaling, such as P53 and p66Shc, further 
enhancing the activation of mPTP. Additionally, mROS causes oxidative damage to calcium transporters, which enhances 
excess loading of mitochondrial calcium that, together with the excess release of mROS, activates additional full opening 
of adjacent mPTP sites. In contrast, modest increases in calcium and/or mROS trigger partial short opening of mPTP, 
releasing small amounts of mROS that, together with slow diffusion of mROS through AQP8, activate mitochondrial pro-
tection mechanisms such as autophagy/mitophagy, UPRmt, NRF2 and PGC1. Additionally, mTORC2 activates SGK1 that 
inhibits the voltage-dependent anion channel (VDAC) from activating mPTP, enabling autophagy/mitophagy to protect 
the cell from the progression of aging. Excessive activation of mPTP turns autophagy/mitophagy into a destructive process 
that leads to cell death. See text for further details. 
3. Autophagy, Aging and mPTP 
Autophagy catabolizes damaged cellular components to protect cells against stress 
and maintain homeostasis [126,127]. There are three types of autophagy: microautophagy, 
in which damaged cellular components are directly sequestered by the lysosomes for deg-
radation, chaperone-mediated autophagy, in which specific motif-containing cargo pro-
teins are delivered to the lysosome by chaperone complexes, and macroautophagy, in 
which damaged cytosolic components, including organelles, are sequestered into double-
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3. Autophagy, Aging and mPTP
Autophagy catabolizes damaged cellular components to protect cells against stress
and maintain homeostasis [126,127]. There are three types of autophagy: microautophagy,
in which damaged cellular components are directly sequestered by the lysosomes for
degradation, chaperone-mediated autophagy, in which specific motif-containing cargo
Cells 2021, 10, 79 6 of 23
proteins are delivered to the lysosome by chaperone complexes, and macroautophagy, in
which damaged cytosolic components, including organelles, are sequestered into double-
membrane autophagosomes that fuse with the lysosome. The macroautophagy process is
mediated by a large number of autophagy-related proteins (ATG) specific to the various
steps of the process (e.g., initiation, formation of a phagophore, cargo sequestration, fusion
of autophagosome with lysosome and degradation of the cargo in the autolysosome). The
process is regulated by the nutrient sensors mTOR and AMP-activated kinase (AMPK),
both of which phosphorylate another kinase, ULK1, which initiates autophagy.
Because autophagy can remove damaged cell components that are associated with
aging, this process, and particularly macrophagy, plays an important role in retarding aging
and aging-related disease [128–134]. A selective form of macroauthophagy is mitophagy,
which specifically removes damaged mitochondria and thus protects the cell from the
deleterious effects of dysfunctional mitochondria, and specifically mitochondria with
activated mPTP (see below). Other selective forms of autophagy that may also play a role in
aging and aging-related disease are: lipophagy, which removes aberrant lipids, aggrephagy,
which removes protein aggregates, and lysophagy, which removes damaged lysosomes.
It has been shown in model organisms (yeast, Drosophila, Caenorhabditis elegans and
mice) that many paradigms of life extension depend on autophagy [34,130,135,136]. These
paradigms include: dietary restriction, mTOR inhibition, reduced insulin/IGF1 signaling,
increased AMPK activity, reduced mitochondrial respiration and reduced TGFb/activin
signaling. Autophagy capacity decreases with age. In model animals, as well as humans,
the expression and activity of autophagy genes is reduced with age in various tissues,
resulting in the accumulation of intermediates of the process, indicating defective au-
tophagy. The overexpression of specific autophagy genes leads to life extension, while the
loss of function of autophagy genes is often associated with age-dependent degenerative
diseases [131,137–139].
AMPK, the major activator of autophagy, is activated by AMP and is very sensitive to
any modulation of the AMP/ADP ratio [140]. An increase in this ratio indicates a reduction
of cellular ATP concentration, signaling a lack of nutrients or other stresses and forcing
a shift in metabolism from anabolic metabolism to catabolic metabolism by activating
AMPK. AMPK phosphorylates ULK1, thereby initiating autophagy [141]. Other activators
of AMPK are a reduction in glucose concentration and, most importantly in the context of
aging and disease, elevated levels of ROS [142–144]. AMPK phosphorylates many other key
enzymes within the autophagy pathways, including key enzymes of mitophagy [145–147].
Another nutrient-sensing pathway that controls autophagy and thus lifespan is the
mTOR pathway [148–152]. There are two branches in the mTOR pathway, mTORC1
and mTORC2. mTORC1 regulates cell growth and metabolism and negatively regulates
autophagy. A lack of nutrients or other stresses inhibit mTORC1 and activate autophagy by
enabling the phosphorylation of ULK1. mTORC2 controls cell proliferation and survival
by the phosphorylation of several protein kinases, including AKT and SGK1.
While autophagy is implicated in several paradigms of life extension and is generally
considered an antiaging mechanism, autophagy is also a well-defined mechanism of cell
death, autophagy-dependent cell death, ADCD [153–155]. It has been shown recently that
what determines whether autophagy is a cell protective mechanism or a cell destructive
mechanism is the activation state of mPTP: when mPTP is inhibited, autophagy is protec-
tive, while overactivation of mPTP turns autophagy into a destructive process [27]. Under
normal conditions, when mTORC2 phosphorylates SGK1, SGK1 phosphorylates VDAC1
at a specific site, and that phosphorylation tags VDAC1 for ubiquitination and proteasomal
degradation, thereby inhibiting mPTP. In C. elegans cells, genetic interference with this
process results in the accumulation of VDAC1 on the outer mitochondrial membrane, and
in the ANT1-dependent activation of mPTP, leading to mitochondrial fragmentation, and a
shorter lifespan. Genetic inhibition of autophagy in these cells restored the normal lifespan.
In addition, genetic or pharmacological inhibition of mPTP increased the lifespan in these
mutants. In SGK1-knockout mouse hepatocytes, the VDAC1 level was elevated, mPTP
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activity was increased, I/R susceptibility was increased and this effect was reversed by
cyclosporin A. In several long-lived C. elegans models, such as calorie restriction or electron
transport protein dysfunction, which are known to depend on autophagy for life extension,
the stimulation of mPTP by VDAC1 overexpression abrogated the autophagy-dependent
life extension. These results strongly suggest that all the antiaging effects of autophagy are
contingent on the inhibition of mPTP activity, supporting the hypothesis that mPTP activity
is critical for the progression of aging [14]. The results of Zhou et al. [27] were corroborated
by recent studies [156,157] that similarly showed that the inactivation of mTORC2 and
SGK1 in C. elegans enhanced autophagic degradation of mitochondria (mitophagy), which
led to developmental and reproductive defects, and was associated with increased release
of mitochondria-derived ROS (most probably resulting from the increased activation of
mPTP, see below).
4. Mitophagy, Aging, mPTP and Parkinson’s Disease
Understanding the critical role of mitophagy and mPTP in the progression of age-
driven neurodegenerative diseases has progressed greatly in recent years, particularly in
relation to the most common neuronal degenerative diseases: Alzheimer’s and Parkinson’s
diseases [158–166]. The role of mPTP in Alzheimer’s disease is discussed in this series
by Heng Du and will not be discussed in this review. To understand the role of mPTP in
Parkinson’s disease, we need to understand the relationship between mitophagy and mPTP.
Mitophagy is a specialized form of autophagy in which damaged mitochondria are
tagged for removal by autophagy [167,168]. There are apparently several pathways to
mitophagy [169,170], but the most important and the better understood one is the canonical
PINK1/PARKIN pathway [171–176]. In this pathway, PTEN-induced kinase 1 (PINK1),
a serin/threonine kinase, accumulates on the mitochondrial outer membrane (MOM)
surface of depolarized and oxidatively stressed mitochondria [177,178]. It recruits the
E3 ubiquitin protein ligase PARKIN to MOM, where it participates in the ubiquitination
of mitochondrial proteins, marking the mitochondria for delivery to autophagosomes
that are taken up by lysosomes. The ubiquitination is not limited to OMM proteins, as
the inner membrane protein prohibitin 2 is also ubiquitinated and this process is critical
for mitophagy [179]. Additionally, Nip3-like protein X (NIX) can mediate mitophagy
independent of the PINK1/PARKIN pathway [169]. Mitophagy is intricately linked to
mitochondrial dynamics [180–182]. In all cells, mitochondria undergo a dynamic cycle
of fission and fusion [181,183–185]. In most cells, and particularly in neurons, the fused
mitochondria consist of long tubular filaments forming an extended network, and there is
a continuous process of fission, that breaks the elongated mitochondria into fragments, and
fusion, that fuses these fragments back into tubular filaments. Mostly, this process serves to
reconfigure the mitochondrial network according to cellular demand. However, damaged
mitochondrial fragments are tagged for autophagy, mostly by the PINK1/PARKIN path-
way [186], while the undamaged fragments, as well as newly synthesized mitochondria, are
fused into elongated tubular filaments. Recent evidence suggests that the fission process is
accelerated by aging [187], while fusion is inhibited [188], thereby increasing mitochondrial
fragmentation in aging. The critical protein for initiating the complex fission process is
dynamin-related protein 1, Drp1, a GTPase that is recruited to fission sites and forms a large
complex around the fission site that initiates the fission process [181,189–192]. Enhanced
Drp1-dependent fission in midlife promotes a healthy lifespan in D. melanogaster [193].
It appears that the same signals that recruit PINK1 to damaged mitochondria also re-
cruit Drp1 to the fission sites, namely mROS and ∆Ψ collapse. This process is mediated
by the phosphorylation of Drp1 by GSK3b (which is activated by ROS) [189], and also
by phosphorylation of MFF, a receptor of DRP1, by AMPK (which is also activated by
ROS) [140,145,146]. Additionally, PINK1, which is recruited to the mitochondria by the col-
lapse of ∆Ψ, also phosphorylates Drp1 [194]. The combination of enhanced mROS and ∆Ψ
collapse is indicative of mPTP activation, and there is direct evidence that mPTP enhances
mitochondrial fission [195]. ROS was also shown to recruit PARKIN to OMM [196,197]. The
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recruitment of PINK1 to damaged mitochondria appears to depend on mPTP activation.
The best known method for the initiation of PINK1 accumulation on OMM is by collapsing
∆Ψ with uncoupler [198], which is known to induce the activation of mPTP [2]. Several
studies showed that the activation of mPTP enhances mitophagy [199]. For example, Q defi-
ciency, which was shown to activate mPTP, increases mitophagy/autophagy, and that effect
was inhibited by cyclosporin, but in Atg5 knockout mice (which inhibits autophagy), Q de-
ficiency resulted in apoptosis [200,201]. Additionally, the overexpression of CypD enhances
mitophagy/autophagy [202]. PINK1 accumulation on OMM also depends on ANT [20] but
it is not clear whether this effect of ANT on mitophagy depends on direct interactions or
results from the dependence of mitophagy on mPTP. Because mitophagy inhibits extended
mPTP activation in the cell by removing fragmented mitochondria with activated mPTP, it
is an important antiaging mechanism. Life extension by calorie restriction or inhibition
of the insulin/IGF1 pathway in C. elegans depends on mitophagy [203]. Similarly, life
extension in C. elegans by urolithin A depends on mitophagy [204]. Mitophagy also retards
aging by inhibiting the formation of the NPLR3 inflammasomes [205–208], which are also,
apparently, induced by mPTP activation [14,164,209]. Figure 2 shows the fission/fusion and
the mitophagy/autophagy processes that clear mPTP-activated mitochondrial fragments
and restore a functional mitochondrial network.
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are taken out by lysosomes, where the damaged mitochondrial fragments are degraded. The undamaged fragments recruit
OPA1 and mitofusins and are fused b ck, together with newly synthe ized mitochondria, i to the mitochondrial network.
Mitophagy was shown to be inhibited in aging [138,160,203,210–212] and this inhi-
bition probably contributed to the enhancement of mPTP activity in aging. One reason
mitophagy is inhibited in aging is the loss of cellular NAD+ in aged cells [89], which, as
discussed above, also partially results from mPTP activation. Similarly, the inhibition of
SIRT3 activity (which depends on NAD+) in aging also inhibits mitophagy [111,213]. Aging
appears to accelerate fission [187], and since aging also inhibits fusion, through the loss of
OPA1 [188], and inhibits mitophagy, the result of these three effects is the enhancement of
mPTP-driven aging and eventual cell death.
Parkinson’s disease is a mitochondrion-dependent, aging-driven, neurodegenera-
tive disease in which the death of dopaminergic neurons, particularly in the substantia
nigra, leads to progressive movement disorders [214,215]. There are two main forms of
Parkinson’s disease: familial and sporadic, and both depend strongly on age. An im-
portant driver of Parkinson’s disease is oxidative stress [216–218]. Major contributors
to the sporadic form of the disease, in addition to aging, are exposure to pesticides and
Cells 2021, 10, 79 9 of 23
other toxins such as rotenone, paraquat and MPP+ that increase ROS production and
activate mPTP [219–226]. The familial forms of Parkinson’s disease result from mutations
in a number of proteins: mitochondrial proteins that participate in mitophagy, PINK1
and Parkin [186,227], LRRK2, a protein that participates in fission [228–231], several ATG
proteins that participate in autophagy [212] and α-synuclein [231]. Thus, the majority
of the familial forms of the disease result from mutations in proteins that participate in
different stages of mitophagy/autophagy, indicating that the disruption of mitophagy is
a major cause of the familial form of the disease [212]. It is not entirely clear how muta-
tions or oxidative damage to α-synuclein result in disease [215,232,233]. However, it was
reported that mutated, aggregated or oxidatively damaged α-synuclein activates mPTP,
apparently by direct interaction with ATP synthase [158,234,235]. It is possible that the
direct activation of mPTP by oxidatively damaged α-synuclein is the major route for the
oxidative stress-induced activation of mPTP in Parkinson’s disease. Since the inhibition
of mitophagy in most of the familial forms of Parkinson’s disease will result in the ac-
cumulation of fragmented mitochondria with activated mPTP, and the toxins that cause
Parkinson’s disease induce the excess production of mROS that activates mPTP, it appears
that the activation of mPTP is the major cause of cell death in Parkinson’s disease. The
ROS-induced activation of mPTP in the electron transport inhibitor model (MPTP+) of
Parkinson’s disease leads to activation of the NLRP3 inflammasome, resulting in the loss
of dopaminergic neurons [164,205]. It is therefore increasingly evident that Parkinson’s
disease, in all of its manifestations, is caused either by the inhibition of mitophagy (which
fails to remove activated mPTP) [169,170,186,192,215,227,236] or by the excessive activation
of mPTP [164,235], as summarized in Figure 3. Aging enhances the production of mROS
and this can increase mPTP activation directly or through oxidative damage to α-synuclein.
Moreover, aging also inhibits mitophagy which explains the strong dependence of Parkin-
son’s disease on aging. Dopaminergic neurons are more susceptible to mPTP activation
than other cells because they are particularly common in aging, causing the overactivation
of mPTP, thereby leading to cell death [237]. The overactivation of autophagy/mitophagy
is a major factor in a variety of other neurodegenerative diseases [238].
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5. Lifespan and Healthspan Extension Paradigms and mPTP
There is currently a great effort to discover drugs, nutritional supplements or lifestyle
modifications that extend lifespan and healthspan [239]. Since current evidence suggests
that mPTP activation accelerates aging and age-driven degenerative disease, it appears
that mPTP itself could be a target for drugs that extend lifespan or retard aging-driven
degenerative disease. Indeed, cyclosporine A was shown to protect against I/R damage and
retard several age-driven diseases [14]. However, cyclosporine is a nonselective inhibitor
of cyclophilins and is known to suppress the immune response, a fact that greatly limits its
utility as an antiaging drug. Cyclosporine derivatives that are more specific for CypD do
show more promise in this regard [240]. Nevertheless, to date, the effort to identify mPTP
inhibitors that are clinically useful has not been successful. While this effort is ongoing,
and may still result in useful drugs [1], it is possible that drugs that directly block mPTP
would not have wide application because these drugs do not distinguish between short
transient openings of mPTP, that are beneficial, and the long full activation of mPTP, which
is damaging. We believe that what is needed is a drug, or other manipulations, that only
inhibit damaging, long, full opening of mPTP and not the short, partial opening that can
be beneficial. Recent data suggest that many lifestyle modifications, drugs and nutritional
supplements that appear to extend lifespan and retard age-driven degenerative disease do
indeed protect against the hyperactivation of mPTP in the context of aging and disease.
As was discussed above, autophagy is a major mechanism to retard aging and aging-
driven degenerative disease, and Zhou et al. [27] demonstrated, in experiments with
C. elegans mutants, that several major autophagy-dependent mechanisms of lifespan
extension depend on mPTP inhibition. Hyperactivation of mPTP in these mutants (by
overexpression of VDAC1) reverses the lifespan extension of these mutations. It is also
clear that the induction of mitophagy, which eliminates fragmented mitochondria with
activated mPTP, is a major contributor to the antiaging effect of autophagy.
Rapamycin, an mTORC inhibitor, extends lifespan and retards aging [241] and it
is well established that rapamycin inhibition of mTORC1 activates autophagy [242–244].
These effects suggest the inhibition of mPTP activity. Indeed, rapamycin was shown to
reverse (the mPTP-induced) mitochondrial fragmentation [242].
Melatonin is a pineal hormone that controls the circadian cycle and is known to have
a protective effect against neurodegeneration, heart disease and cancer, which is mediated
through the inhibition of mPTP [245–249]. It has been shown that melatonin is a potent
inhibitor of mPTP in isolated mitoplasts [250]. However, the exact mechanism of inhibition
is not clear. Highly significant is the observation that melatonin does not inhibit the
transient (and beneficial) opening of mPTP [251]. It is therefore clear that the inhibition of
mPTP by melatonin is indirect, and that melatonin only inhibits the damaging full opening
of mPTP. This conclusion is also supported by the fact that melatonin is a widely used
supplement, taken by millions of people, apparently without any deleterious effects.
Metformin is a widely used antidiabetic drug that has been shown to extend lifespan in
animal models of aging, and to increase human healthspan [252–254]. Metformin was also
reported to activate mitophagy [255]. It is known that metformin directly inhibits NADH
dehydrogenase, and it was shown that this inhibition leads to the inhibition of mPTP and
protection from I/R damage [256–258]. However, it is not known how the inhibition of
NADH dehydrogenase translates into the inhibition of mPTP. Apparently, the enhancement
of mROS production that results from the inhibition of NADH dehydrogenase activates
autophagy by inhibiting mTORC1 [252,259] and by activation of AMPK [260,261]. Thus,
metformin may be another example of a drug that inhibits only the aging-inducing full
activation of mPTP, but does not inhibit the beneficial transient opening of mPTP.
Resveratrol, an antioxidant, is known to enhance healthspan [262]. Resveratrol was
shown to enhance autophagy and mitophagy [263,264], and it appears that this effect also
depends on the inhibition of mPTP [265–268]. Resveratrol protects against I/R damage in
myocytes by the dephosphorylation of VDAC1, which inhibits mPTP [268]. Similarly, pro-
tection from ER stress by resveratrol depends on the inhibition of mPTP [269]. Resveratrol
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was also shown to protect against neurodegeneration by activating sirt1 which activates
PGC1a that accelerates mitochondrial biogenesis (which replaces mPTP-damaged mito-
chondria with newly minted mitochondria) [270,271]. Resveratrol activation of sirt3 (which
inhibits mPTP) was also demonstrated in several studies [271–273].
Spermidine is a known inducer of autophagy [263,274] and has been shown to be
an effective antiaging agent [275–277]. Spermidine induces autophagy by inducing the
synthesis of the autophagy transcription factor TFEB [278] through the AMPK–mTORC1–
ULK1 pathway [274]. It was shown to provide cardioprotection and to extend life in mice
through the activation of autophagy and mitophagy [276]. Spermine, a metabolite of
spermidine, also has a cardioprotection effect [279]. Therefore, it is more than likely that
there is also a direct effect of spermidine on mPTP since spermine and other polyamines
have been shown to inhibit mPTP in isolated mitochondria [280–282].
Exercise and dietary restriction are two known lifestyle modifications that enhance
healthspan. Exercise is a well-established lifestyle modification that retards aging and
increases human healthspan [283]. Exercise enhances mitophagy and autophagy [284,285],
which are associated with the inhibition of mPTP. It was shown that exercise training
decreases susceptibility to Ca2+-induced mPTP opening in heart mitochondria [286]. It was
also demonstrated that endurance exercise in hyperglycemic rats decreases susceptibility
to mPTP opening in isolated heart mitochondria [287]. Similarly, exercise protects against
the enhanced mPTP opening in heart mitochondria of rats treated with doxorubicin [288].
Dietary restrictions have been shown to increase lifespan and healthspan in all animal
models of aging (e.g., yeast, C. elegans, Drosophila, mouse) [239,289–291]. It is evident that
the nutrient-sensing mTOR and the insulin/IGF1 pathways mediate the effect of dietary
restriction on aging [149,291]. However, the mechanism(s) that lead from these signals
to life extension are not entirely clear. Apparently, induction of autophagy, mitophagy,
mitochondrial metabolism modification or antioxidant response could be the critical el-
ement in various paradigms of dietary restriction [292]. Nevertheless, it is also evident
that these pathways may all result, directly or indirectly, in the inhibition of mPTP. Several
studies demonstrated that dietary restriction prevents mPTP opening in liver and brain
mitochondria [293–295], but not in the skeletal muscle or heart [296]. Zhou et al. [27]
showed that the increased lifespan of the calorie-restricted eat-2 C. elegans mutant is de-
pendent on the inhibition of mPTP, similar to other autophagy-dependent life extension
paradigms. Dietary restriction in humans was shown to reduce oxidative stress [297], and
since oxidative stress is both a major cause of enhanced mPTP activity, and an outcome of
enhanced mPTP activation [14], it is likely that mPTP activity is reduced in ageing humans
subjected to dietary restrictions.
6. Conclusions
Almost half a century ago, it was first proposed in the mitochondrial free radical
theory of aging that mitochondrial reactive oxygen species, mROS, are the major cause
of aging and thus determine the lifespan of animals and humans. Four decades ago, the
mitochondrial permeability transition pore, mPTP, was first discovered, and two decades
ago, it was first shown that mPTP activity is enhanced in aging. Over the last two decades,
extensive research on aging and aging-driven degenerative diseases, and on the many
pathways that control mPTP activation, have brought these apparently unrelated fields
together into an emerging understanding of the connection between these phenomena.
While the mitochondrial free radical theory of aging first appeared to be challenged by
the discovery that mROS signaling actually protects against aging and disease, there is
now a better understanding of the role of mROS signaling, driven by a modest increase
in mROS production, in activating protective mechanisms against the damaging effect
of excess mROS production. Moreover, it is becoming clear that mPTP plays a critical
role both in mROS signaling, by partial, short openings of the pore that release small
amount of mROS, and in mROS-induced aging, by the full, extended opening of mPTP
that releases large amounts of mROS and NAD+ that damage the cell and accelerate
Cells 2021, 10, 79 12 of 23
aging and aging-dependent diseases. Recent studies show how the complex control of
mPTP activity can play a critical role in both the mechanisms that protect the cell from
aging and disease, and in the mechanisms that accelerate aging and drive the aging-
dependent degenerative diseases. The major pathways that control the activity of mPTP
are summarized schematically in Figure 1. In particular, the recent discovery that mPTP
activity determines whether autophagy/mitophagy protects from aging and disease or
accelerates cell aging and death greatly clarifies the decisive role of mPTP in aging and
disease and can guide the discovery of new drugs and lifestyle modification that enhance
healthspan and lifespan.
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